Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{189153,
        author = {KANDANURU VENKATA VISWANATH and Chandu Rachapogu and Swaroop K. R. Rachamreddy and Janani Jadapalli and KolavaliYallaReddy},
        title = {An Examination and Treatment of Parkinson's Disease and Its Effects on Enhancing Motor Symptoms at Tertiary Care Hospitals},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {7},
        pages = {4962-4971},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=189153},
        abstract = {Parkinson’s disease (PD) is an age-related neurodegenerative brain disorder caused due to death of dopaminergic neurons that regulate movement in the substantia nigra pars compacta in Basal Ganglia. There is a global prevalence of rising cases of 6.1 million in 2016 to an expected 12 million cases in 2050. This study aims to determine methods to Improve the disorder's symptomatic motor and nonmotor features by collecting 120 cases at tertiary care hospital. Study shows men are affected slightly more rather than females. Elevated motor symptoms are mainly Tremors, rather than rigidity, bradykinesia, and postural instability. Nonmotor symptoms like Depression, Anxiety, sleeplessness, etc., have been observed. This study mostly diagnoses PD by physical observations and MRI scans. Motor improvements are extensively achieved by Levodopa and Carbidopa which are crucial prescribed regimens other than Dopamine Agonists, and MAO/COMT inhibitors. Discharge follow-up is not accompanied in this study. Management of PD is complex, and ongoing research provides significant advancements in the treatment of Parkinson’s disease.},
        keywords = {Parkinson’s disease, Levodopa, Carbidopa, Pramipexole, Selegiline, Entacapone.},
        month = {December},
        }